 |
88 Diseases |  |
68 Trials |
|
68 Trials |  |
2888 News |  |
| «12...24252627282930313233343536» |
- leflunomide / Generic mfg.
Trial primary completion date: Leflunomide for Maintenance of Remission in IgG4 Related Disease (clinicaltrials.gov) - Apr 7, 2016
P4, N=66, Recruiting, Sponsor: Chinese PLA General Hospital
Trial primary completion date: Jul 2018 --> Mar 2019
- leflunomide / Generic mfg.
Enrollment open: Leflunomide for Maintenance of Remission in IgG4 Related Disease (clinicaltrials.gov) - Apr 7, 2016
P4, N=66, Recruiting, Sponsor: Chinese PLA General Hospital
Trial primary completion date: Jul 2018 --> Mar 2019 Not yet recruiting --> Recruiting
- | leflunomide / Generic mfg.
New P4 trial: Leflunomide for Maintenance of Remission in IgG4 Related Disease (clinicaltrials.gov) - Mar 9, 2016
P4, N=66, Not yet recruiting, Sponsor: Chinese PLA General Hospital
- |||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date, Combination therapy, Monotherapy: A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 4, 2016
P3, N=100, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2017 --> Jul 2016
- | hydroxychloroquine / Generic mfg., leflunomide / Generic mfg.
New P4 trial: Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis (clinicaltrials.gov) - Dec 31, 2015
P4, N=180, Recruiting, Sponsor: Jawaharlal Institute of Postgraduate Medical Education & Research
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA (clinicaltrials.gov) - Dec 3, 2015
P4, N=200, Recruiting, Sponsor: University of Illinois at Chicago
Trial primary completion date: Apr 2017 --> Jul 2016 Not yet recruiting --> Recruiting
- leflunomide / Generic mfg.
Enrollment open, Trial primary completion date: Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 8, 2015
P1, N=42, Recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Nov 2017
- ||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed, Monotherapy: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) (clinicaltrials.gov) - Oct 20, 2015
P3, N=90, Active, not recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Nov 2017 Recruiting --> Active, not recruiting
- |||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date, Combination therapy, Monotherapy: A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 2, 2015
P3, N=100, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Apr 2017
- | prednisone / Generic mfg.
Clinical: The Research of Standard Diagnosis and Treatment for HSPN in Children (clinicaltrials.gov) - Aug 26, 2015
P2, N=100, Recruiting, Sponsor: Nanjing Children's Hospital
- leflunomide / Generic mfg.
New P1 trial: Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 27, 2015
P1, N=42, Not yet recruiting, Sponsor: City of Hope Medical Center
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed, Combination therapy, Monotherapy: A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 2, 2015
P3, N=100, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2015 --> Apr 2017 Recruiting --> Active, not recruiting
- || leflunomide / Generic mfg.
Trial primary completion date: An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria (clinicaltrials.gov) - Jun 11, 2015
P2, N=60, Recruiting, Sponsor: Changzheng-Cinkate
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2014 --> Dec 2015
- Trial completion: CareRA: Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis. (clinicaltrials.gov) - Jun 10, 2015
P4, N=400, Completed, Sponsor: P. Verschueren
Trial primary completion date: Jul 2014 --> Dec 2015 Active, not recruiting --> Completed
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA (clinicaltrials.gov) - May 22, 2015
P4, N=200, Not yet recruiting, Sponsor: University of Illinois at Chicago
- ||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial completion: To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) (clinicaltrials.gov) - Apr 30, 2015
P3, N=522, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Apr 25, 2015
P3, N=156, Completed, Sponsor: Frank Behrens
Active, not recruiting --> Completed Recruiting --> Completed | N=270 --> 156 | Trial primary completion date: Dec 2013 --> Feb 2015
- |||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open, Monotherapy: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) (clinicaltrials.gov) - Mar 28, 2015
P3, N=90, Recruiting, Sponsor: Sanofi
Recruiting --> Completed | N=270 --> 156 | Trial primary completion date: Dec 2013 --> Feb 2015 Not yet recruiting --> Recruiting
- ||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed: SARIL-RA-EASY: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 5, 2015
P3, N=200, Active, not recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed: To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) (clinicaltrials.gov) - Mar 5, 2015
P3, N=522, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial, Monotherapy: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) (clinicaltrials.gov) - Feb 26, 2015
P3, N=90, Not yet recruiting, Sponsor: Sanofi
- leflunomide / Generic mfg.
Trial completion: A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=304, Completed, Sponsor: The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date, MRI: Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study (clinicaltrials.gov) - Dec 5, 2014
P4, N=1, Terminated, Sponsor: Singapore General Hospital
Recruiting --> Completed N=20 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2012
- ||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial completion: To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (clinicaltrials.gov) - Nov 18, 2014
P3, N=202, Completed, Sponsor: Sanofi
N=20 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2012 Active, not recruiting --> Completed
- ||||| Iremod (iguratimod) / Simcere
New P4 trial, Combination therapy: Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 27, 2014
P4, N=240, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies (clinicaltrials.gov) - Sep 30, 2014
P3, N=2067, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Apr 2013
- ||| staphylococcal protein A (PRTX-100) / Protalex
Trial completion, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 18, 2014
P1, N=61, Completed, Sponsor: Protalex, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Apr 2013 Active, not recruiting --> Completed
- | Enbrel (etanercept) / Pfizer, Amgen
Phase classification, Real-world evidence, Real-world: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=6393, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Phase classification: P4 --> P=N/A
- ||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed: To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (clinicaltrials.gov) - Jul 18, 2014
P3, N=200, Active, not recruiting, Sponsor: Sanofi
Phase classification: P4 --> P=N/A Recruiting --> Active, not recruiting
- |||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date: To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (clinicaltrials.gov) - Jun 13, 2014
P3, N=200, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Nov 2014
- || staphylococcal protein A (PRTX-100) / Protalex
Trial primary completion date, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2014
P1, N=64, Active, not recruiting, Sponsor: Protalex, Inc.
Trial primary completion date: Feb 2015 --> Nov 2014 Trial primary completion date: Apr 2014 --> Aug 2014
- | staphylococcal protein A (PRTX-100) / Protalex
Trial completion date, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2014
P1, N=64, Active, not recruiting, Sponsor: Protalex, Inc.
Trial primary completion date: Apr 2014 --> Aug 2014 Trial completion date: Aug 2014 --> Sep 2014
- |||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open: SARIL-RA-EASY: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 23, 2014
P3, N=200, Recruiting, Sponsor: Sanofi
Trial completion date: Aug 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- ||||||| Orencia (abatacept) / BMS
Trial completion: Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy (clinicaltrials.gov) - Feb 22, 2014
P3, N=1286, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- pateclizumab (RG7416) / Roche
Trial completion, Combination therapy: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 9, 2014
P2, N=211, Completed, Sponsor: Genentech
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial: SARIL-RA-EASY: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 5, 2014
P3, N=200, Recruiting, Sponsor: Sanofi
- || staphylococcal protein A (PRTX-100) / Protalex
Enrollment closed, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 5, 2014
P1, N=64, Active, not recruiting, Sponsor: Protalex, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed: CareRA: Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis. (clinicaltrials.gov) - Jan 27, 2014
P4, N=400, Active, not recruiting, Sponsor: P. Verschueren
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel) (clinicaltrials.gov) - Jan 5, 2014
P4, N=210, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | hydroxychloroquine / Generic mfg., sulfasalazine / Generic mfg., leflunomide / Generic mfg.
Enrollment change: Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis (clinicaltrials.gov) - Jan 1, 2014
P3, N=70, Completed, Sponsor: University of Nebraska
Active, not recruiting --> Completed N=180 --> 70
- leflunomide / Generic mfg.
New P4 trial, Adverse events: Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Dec 29, 2013
P4, N=30, Recruiting, Sponsor: Mashhad University of Medical Sciences
- Zelboraf (vemurafenib) / Roche
Trial suspension, Combination therapy, Metastases: Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma (clinicaltrials.gov) - Dec 23, 2013
P1/2, N=55, Suspended, Sponsor: Massachusetts General Hospital
N=180 --> 70 Recruiting --> Suspended
- leflunomide / Generic mfg.
Trial completion, Head-to-Head: Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood (clinicaltrials.gov) - Dec 11, 2013
P=N/A, N=15, Completed, Sponsor: Chinese Academy of Sciences
Recruiting --> Suspended Recruiting --> Completed
- ||||| Ocrevus (ocrelizumab) / Roche
Enrollment closed: A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-? Therapy (SCRIPT) (clinicaltrials.gov) - Dec 4, 2013
P3, N=840, Active, not recruiting, Sponsor: Genentech
Recruiting --> Completed Terminated --> Active, not recruiting
- |||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment open, Combination therapy, Monotherapy: A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 25, 2013
P3, N=100, Recruiting, Sponsor: Hoffmann-La Roche
Terminated --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Nov 17, 2013
P3, N=89, Completed, Sponsor: JW Pharmaceutical
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || staphylococcal protein A (PRTX-100) / Protalex
Enrollment change, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - Sep 22, 2013
P1, N=64, Active, not recruiting, Sponsor: Protalex, Inc.
Active, not recruiting --> Completed N=52 --> 64
- |||||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial, Combination therapy, Monotherapy: A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 11, 2013
P3, N=100, Recruiting, Sponsor: Hoffmann-La Roche
- |||| leflunomide / Generic mfg.
Enrollment open: An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria (clinicaltrials.gov) - Sep 5, 2013
P2, N=60, Recruiting, Sponsor: Changzheng-Cinkate
N=52 --> 64 Not yet recruiting --> Recruiting
- leflunomide / Generic mfg.
Enrollment open: A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome (clinicaltrials.gov) - Jul 29, 2013
P=N/A, N=304, Recruiting, Sponsor: The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting